Chiang Mai, Thailand — November 24, 2025
Hemogen Therapeutics was invited to participate in the inaugural meeting of the Southeast Asia Thalassemia Prevention Alliance (SEATPA), launched by BGI Group in collaboration with the Thai Ministry of Public Health, Chiang Mai University, renowned genomics research experts from hospitals, and representatives from the China Marrow Donor Program which is administered by the Red Cross Society of China.
Thalassemia remains highly prevalent across Southeast Asia, and Hemogen shared updates on the progress of its HGI-001 gene therapy program and its collaborative model for enabling sustainable treatment capacity in high-burden countries.
Since 2023, Hemogen has advanced the local deployment of HGI-001 in Thailand. In April 2025, the program received Investigational New Drug (IND) approval from the Thai Food and Drug Administration (Thai FDA). Feasibility has now been validated for treatment-pathway adaptation, institutional workflow alignment, and local cell-processing and delivery models, with first-patient enrollment expected by the end of this year.
SPARK: Hemogen’s Integrated Solution for Global Gene Therapy Deployment
At the core of Hemogen’s international strategy is SPARK—a comprehensive, end-to-end solution designed to help partners rapidly establish local clinical-grade gene therapy capabilities. SPARK integrates the full technological, regulatory, and operational foundations required for sustainable implementation:
S – Service & Support: Expert technical guidance, operational assistance, and training throughout implementation.
P – Platform: A full R&D-to-manufacturing platform anchored by Hemogen’s proprietary Celaxi-23 automated cell-processing system.
A – All-in-One Kits: Standardized, ready-to-use manufacture kits ensuring reproducibility and streamlined workflows.
R – Regulatory: Comprehensive regulatory documentation and quality-system frameworks aligned with international standards.
K – Knowledge & Know-How: Structured technology transfer enabling partners to fully adopt Hemogen’s proprietary processes and critical expertise.
Beyond integrating these capabilities, SPARK represents the “spark of hope”—with Thailand becoming the first validated deployment site and a starting point for scalable, region-wide access to innovative thalassemia gene therapy in Southeast Asia.
Regional and Global Collaboration Outlook
Hemogen is extending the SPARK model to additional Southeast Asian countries and strengthening cross-border collaboration through the Shenzhen–Hong Kong innovation corridor, enabling efficient regulatory alignment and clinical execution. The company is also expanding partnerships in the Middle East, where demand for CGT infrastructure and localized manufacturing is rapidly increasing. Through SPARK, Hemogen aims to support global partners in building sustainable, scalable gene therapy capabilities and advancing long-term access to curative treatments for inherited diseases.
